Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Resistin in idiopathic inflammatory myopathies

M. Filková, H. Hulejová, K. Kuncová, L. Pleštilová, LA. Cerezo, H. Mann, M. Klein, J. Zámečník, S. Gay, J. Vencovský, L. Senolt,

. 2012 ; 14 (3) : R111.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NS10614 MZ0 CEP Register

INTRODUCTION: The purpose of this study was to evaluate and compare the serum levels and local expression of resistin in patients with idiopathic inflammatory myopathies to controls, and to determine the relationship between resistin levels, inflammation and disease activity. METHODS: Serum resistin levels were determined in 42 patients with inflammatory myopathies and 27 healthy controls. The association among resistin levels, inflammation, global disease activity and muscle strength was examined. The expression of resistin in muscle tissues from patients with inflammatory myopathies and healthy controls was evaluated. Gene expression and protein release from resistin-stimulated muscle and mononuclear cells were assessed. RESULTS: In patients with inflammatory myopathies, the serum levels of resistin were significantly higher than those observed in controls (8.53 ± 6.84 vs. 4.54 ± 1.08 ng/ml, P < 0.0001) and correlated with C-reactive protein (CRP) levels (r = 0.328, P = 0.044) and myositis disease activity assessment visual analogue scales (MYOACT) (r = 0.382, P = 0.026). Stronger association was observed between the levels of serum resistin and CRP levels (r = 0.717, P = 0.037) as well as MYOACT (r = 0.798, P = 0.007), and there was a trend towards correlation between serum resistin and myoglobin levels (r = 0.650, P = 0.067) in anti-Jo-1 positive patients. Furthermore, in patients with dermatomyositis, serum resistin levels significantly correlated with MYOACT (r = 0.667, P = 0.001), creatine kinase (r = 0.739, P = 0.001) and myoglobin levels (r = 0.791, P = 0.0003) and showed a trend towards correlation with CRP levels (r = 0.447, P = 0.067). Resistin expression in muscle tissue was significantly higher in patients with inflammatory myopathies compared to controls, and resistin induced the expression of interleukins (IL)-1β and IL-6 and monocyte chemoattractant protein (MCP)-1 in mononuclear cells but not in myocytes. CONCLUSIONS: The results of this study indicate that higher levels of serum resistin are associated with inflammation, higher global disease activity index and muscle injury in patients with myositis-specific anti-Jo-1 antibody and patients with dermatomyositis. Furthermore, up-regulation of resistin in muscle tissue and resistin-induced synthesis of pro-inflammatory cytokines in mononuclear cells suggest a potential role for resistin in the pathogenesis of inflammatory myopathies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024434
003      
CZ-PrNML
005      
20200205124139.0
007      
ta
008      
130703s2012 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/ar3836 $2 doi
035    __
$a (PubMed)22577940
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Filková, Mária $u Institute of Rheumatology, Department of Experimental Rheumatology of the 1st Faculty of Medicine, Charles University in Prague, Na Slupi 4, Prague 2, 128 50, Czech Republic.
245    10
$a Resistin in idiopathic inflammatory myopathies / $c M. Filková, H. Hulejová, K. Kuncová, L. Pleštilová, LA. Cerezo, H. Mann, M. Klein, J. Zámečník, S. Gay, J. Vencovský, L. Senolt,
520    9_
$a INTRODUCTION: The purpose of this study was to evaluate and compare the serum levels and local expression of resistin in patients with idiopathic inflammatory myopathies to controls, and to determine the relationship between resistin levels, inflammation and disease activity. METHODS: Serum resistin levels were determined in 42 patients with inflammatory myopathies and 27 healthy controls. The association among resistin levels, inflammation, global disease activity and muscle strength was examined. The expression of resistin in muscle tissues from patients with inflammatory myopathies and healthy controls was evaluated. Gene expression and protein release from resistin-stimulated muscle and mononuclear cells were assessed. RESULTS: In patients with inflammatory myopathies, the serum levels of resistin were significantly higher than those observed in controls (8.53 ± 6.84 vs. 4.54 ± 1.08 ng/ml, P < 0.0001) and correlated with C-reactive protein (CRP) levels (r = 0.328, P = 0.044) and myositis disease activity assessment visual analogue scales (MYOACT) (r = 0.382, P = 0.026). Stronger association was observed between the levels of serum resistin and CRP levels (r = 0.717, P = 0.037) as well as MYOACT (r = 0.798, P = 0.007), and there was a trend towards correlation between serum resistin and myoglobin levels (r = 0.650, P = 0.067) in anti-Jo-1 positive patients. Furthermore, in patients with dermatomyositis, serum resistin levels significantly correlated with MYOACT (r = 0.667, P = 0.001), creatine kinase (r = 0.739, P = 0.001) and myoglobin levels (r = 0.791, P = 0.0003) and showed a trend towards correlation with CRP levels (r = 0.447, P = 0.067). Resistin expression in muscle tissue was significantly higher in patients with inflammatory myopathies compared to controls, and resistin induced the expression of interleukins (IL)-1β and IL-6 and monocyte chemoattractant protein (MCP)-1 in mononuclear cells but not in myocytes. CONCLUSIONS: The results of this study indicate that higher levels of serum resistin are associated with inflammation, higher global disease activity index and muscle injury in patients with myositis-specific anti-Jo-1 antibody and patients with dermatomyositis. Furthermore, up-regulation of resistin in muscle tissue and resistin-induced synthesis of pro-inflammatory cytokines in mononuclear cells suggest a potential role for resistin in the pathogenesis of inflammatory myopathies.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myozitida $x krev $x imunologie $x patologie $7 D009220
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a resistin $x krev $7 D052243
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hulejová, Hana $u -
700    1_
$a Kuncová, Klára $u -
700    1_
$a Pleštilová, Lenka $u -
700    1_
$a Cerezo, Lucie Andrés $u -
700    1_
$a Mann, Heřman, $d 1973- $7 nlk20010095506
700    1_
$a Klein, Martin $u -
700    1_
$a Zámečník, Josef $u -
700    1_
$a Gay, Steffen $u -
700    1_
$a Vencovský, Jiří $u -
700    1_
$a Senolt, Ladislav $u -
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 14, č. 3 (2012), s. R111
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22577940 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20200205124527 $b ABA008
999    __
$a ok $b bmc $g 988114 $s 822814
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 14 $c 3 $d R111 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
GRA    __
$a NS10614 $p MZ0
LZP    __
$a Pubmed-20130703

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...